0001136261-22-000041.txt : 20220111 0001136261-22-000041.hdr.sgml : 20220111 20220111162732 ACCESSION NUMBER: 0001136261-22-000041 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220110 FILED AS OF DATE: 20220111 DATE AS OF CHANGE: 20220111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Golembiewski Michael Joseph CENTRAL INDEX KEY: 0001639479 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22245 FILM NUMBER: 22524196 MAIL ADDRESS: STREET 1: 7 TURTLE CT CITY: FLEMINGTON STATE: NJ ZIP: 08822 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 4 1 ownership.xml X0306 4 2022-01-10 0 0001017491 SEELOS THERAPEUTICS, INC. SEEL 0001639479 Golembiewski Michael Joseph C/O SEELOS THERAPEUTICS, INC. 300 PARK AVENUE, 2ND FLOOR NEW YORK NY 10022 0 1 0 0 Chief Financial Officer Stock Option (right to buy) 1.46 2022-01-10 4 A 0 500000 0.00 A 2032-01-10 Common Stock 500000 500000 D 1/4th of the shares subject to the option shall vest on January 10, 2023, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through such vesting date. /s/ Michael Golembiewski 2022-01-11